Patient came to hospital for upper limp surgeries and we used brachial plexus block using ultrasound guided retro clavicular approach using levobupivacaine and comparing dexmedetomidine and dexamethasone as adjuvants to it.

Comparative Study Between Dexmedetomidine Versus Dexamethasone As An Adjuvant To Levobupivacaine In Ultrasound Guided Retro clavicular Brachial Plexus Block In Patients Undergoing Upper Limb Surgeries - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105599

Enrollment

Registered

2026-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S599- Unspecified injury of elbow and forearm

Interventions

Intervention1: Injection dexmedetomidine: inj Levobupivacaine 0.5 % 18 ml + inj Dexmedetomedine ( 0.3 ml+1.7ml saline )=20ml Control Intervention1: Injection Dexamethasone: inj Levobupivacaine 0.

Eligibility

Inclusion criteria

Inclusion criteria: Patients scheduled for upper limb surgeries where ultrasound guided retroclavicular brachial plexus block is to be given Age 18-65yrs All genders ASA grade 1 or 2

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
To assess and compare onset and duration of sensory and motor block between the groupsTimepoint: Motor blockade scale at 0,5,10,15,20,25,30 mins	—

Secondary

Measure	Time frame
To assess and compare - Postoperative VAS score Haemodynamic parameters (HR,SBP,DBP,MAP) The time to requirement of first rescue analgesia Postoperative complications if any Timepoint: 0 minutes, 30 minutes, 1 hour, 2 hour, 3 hour,6 hour, 12 hour	—

Countries

India

Contacts

Public ContactDr Mangilal Deganwa

Mahatma Gandhi Medical College And Hospital

mangilaldeganwa0606@gmail.com9871495240

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026